This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Corneal Disorders  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Olga Zinchuk, MD, PhD; Makio Watanabe, MD, PhD; Nobutsugu Hayashi, MD, PhD; Atsuki Fukushima, MD, PhD; Hisayuki Ueno, MD, PhD

Arch Ophthalmol. 2006;124:1046-1048.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Tamoxifen citrate (ICI46474) is an antiestrogenic agent¹ used in cases of disseminated breast carcinomas and as adjuvant postoperative therapy. Toxic reactions to tamoxifen, such as decreased visual acuity, bilateral macular edema, and yellow-white dots in the paramacular and foveal areas, are relatively rare (reported incidence between 0.9%-12%^2-3).

In 1978, Kaiser-Kupfer and Lippman⁴ first reported the occurrence of what has become known as tamoxifen keratopathy and tamoxifen retinopathy in 4 women treated with very high doses (up to 320 mg per day) of tamoxifen citrate for longer than 1 year. The typical findings were bilateral white, whorl-like, central, subepithelial opacities in the cornea. They also found white refractive opacities superficial to retinal blood vessels, forming clusters located in the paramacular and foveal areas, with the highest concentration temporally, and . . . [Full Text of this Article]

Report of a Case


Comment

AUTHOR INFORMATION